We’re proud to announce that we’ve been recognized with a Frost & Sullivan 2023 Customer Value Leadership Award.
Dramatically shorten your drug development timeline & improve chances of success through comprehensive and informative biomarker analysis
Learn more about what is happening in the tumor microenvironment of your tissue sample
Benefit from our vast experience developing novel pathology tests in a regulated setting
Powered by award-winning, proprietary technology and a multidisciplinary team of experts, Flagship Biosciences brings simplicity to a complicated pathology world.
From developing and validating an assay to employing the most comprehensive image analysis data, we provide a full, end-to-end solution for discovering and contextualizing the most relevant endpoints in a CAP/CLIA or RUO setting.
Our unique, proprietary image analysis technology provides thousands of measurements on every cell across an entire slide for validated spatial insights on every sample. Flagship’s technology, team, and proven process have provided superior data for hundreds of clinical trials.
Quite simply, we’re changing the drug development paradigm.
Cell-based image analysis, assays, and partnership to advance clinical trials and regulatory acceptance.
Dependable clinical diagnostic testing to connect patients to individualized, immuno-oncology therapies.
Download our recent white paper,
“Tissue Image Analysis and Biomarker Assessment Implementation Benefits and ROI”
More accurate and informative tissue data and analytics
Collaboration with our world-renowned scientific team
Increased speed to market for your drug development programs
Enriched clinical diagnostics process for better outcomes